{
  "@context": "https://frontierpicks.com/schemas/dossier.v1.json",
  "ticker": "EPRX",
  "name": "Eupraxia Pharmaceuticals Inc.",
  "url": "https://frontierpicks.com/dossiers/EPRX/",
  "json_url": "https://frontierpicks.com/dossiers/EPRX.json",
  "status": "DORMANT",
  "current_conviction": "LOW",
  "archetype": {
    "code": "a5",
    "n": 5
  },
  "current_thesis": "Eupraxia Pharmaceuticals' once-a-year EoE steroid injection, EP-104GI, is priced on open-label data from 14 patients, and the shares have rallied into a 13 November 2026 Analyst Day. The December 2026 placebo-controlled Phase 2b interim settles the case.",
  "invalidation_trigger": "A daily close above $9.10, over the late-September 2026 data-release peak, which would show the shares leading the S&P 500. A December 2026 interim in which EP-104GI arms separate from placebo on the primary endpoint would also show the shares leading.",
  "catalyst_date": "2026-11-13",
  "portfolio": null,
  "pick": null,
  "themes": [
    "binary-catalyst-biotech"
  ],
  "tags": [],
  "sources": [],
  "caveats": [],
  "source_links": [
    {
      "title": "Eupraxia Pharmaceuticals Pivots Strategy: Focuses Capital on Lead Asset as Expenses Rise",
      "url": "https://www.panabee.com/news/eupraxia-pharmaceuticals-earnings-q3-2026",
      "date": null
    },
    {
      "title": "BioPharmaWatch",
      "url": "https://www.biopharmawatch.com/news/EPRX/eupraxia-pharmaceuticals-at-the-market-offering",
      "date": null
    }
  ],
  "evidence": [
    {
      "claim": "9 of 14 patients (64%) in RESOLVE cohorts 5-9 remained in clinical remission 52 weeks after a single EP-104GI administration; cohort 9 (n=3) had 2 of 3 in remission.",
      "source": "Company press release, 2026-09-30 (GlobeNewswire)",
      "as_of": "2026-09-30"
    },
    {
      "claim": "Eupraxia reached its target enrollment of 120 patients in the placebo-controlled, blinded Phase 2b portion of RESOLVE; interim results are expected in December 2026.",
      "source": "Company news release, 2026-10-15",
      "as_of": "2026-10-15"
    },
    {
      "claim": "Cash and equivalents were $75.2M and short-term investments $51.2M at 2026-09-30; the company guides runway into the second half of 2028.",
      "source": "Q3 2026 results, as reported by Panabee",
      "as_of": "2026-09-30"
    },
    {
      "claim": "Eupraxia established a $125 million at-the-market equity program and said it has no current plan to use it in the near term.",
      "source": "Company announcement headline, 2026-11-10",
      "as_of": "2026-11-10"
    },
    {
      "claim": "Q3 2026 loss per share was $0.23 against a $0.28 estimate.",
      "source": "Company Q3 2026 results headline, 2026-11-10",
      "as_of": "2026-11-10"
    },
    {
      "claim": "RBC Capital Markets initiated coverage of Eupraxia with an Outperform rating.",
      "source": "News headline, 2026-11-09",
      "as_of": "2026-11-09"
    },
    {
      "claim": "H.C. Wainwright maintained Buy and raised its price target to $16.",
      "source": "News headline, 2026-11-11",
      "as_of": "2026-11-11"
    },
    {
      "claim": "The 2026-02-20 offering sold 7,607,145 shares at $7.00 plus 1,428,571 pre-funded warrants; shares outstanding were 65.5M at 2026-06-30.",
      "source": "H1 2026 interim financial statements (Form 6-K)",
      "as_of": "2026-06-30"
    }
  ],
  "view_changes": [],
  "frame": null,
  "filed_numbers": {
    "as_of": "2026-11-13",
    "sector": "Healthcare",
    "financials": {
      "status": "not available",
      "reason": "no quarterly report in US GAAP with the SEC (a foreign filer reports on Form 20-F or 40-F)",
      "close_date": "2026-11-13",
      "latest_quarter": null,
      "figures": {}
    },
    "short_interest": {
      "status": "ok",
      "settlement": "2026-10-15",
      "published": "2026-10-26",
      "short_pct_of_outstanding": null,
      "days_to_cover": 5.2,
      "change_pct": -3.8
    },
    "insiders": {
      "status": "ok",
      "as_of": "2026-11-15",
      "windows": [
        {
          "days": 90,
          "status": "ok",
          "from": "2026-08-18",
          "bought_usd": 0,
          "sold_usd": 0,
          "bought_unpriced": 0,
          "sold_unpriced": 0
        },
        {
          "days": 365,
          "status": "ok",
          "from": "2025-11-16",
          "bought_usd": 0,
          "sold_usd": 0,
          "bought_unpriced": 0,
          "sold_unpriced": 0
        }
      ]
    }
  },
  "body_markdown": "## Current Thesis\n\nEupraxia Pharmaceuticals' once-a-year steroid injection for eosinophilic esophagitis (EoE), EP-104GI, is priced on open-label remission data from 14 patients, and the shares are more likely to lag the S&P 500 than lead it over the next three months. The December 2026 interim from the randomized, placebo-controlled Phase 2b portion of the RESOLVE trial, fully enrolled at 120 patients, settles the case.\n\nThe shares closed at $8.06 on 2026-11-11, up from $6.60 on 2026-11-05. The rise came as RBC Capital Markets initiated coverage with an Outperform rating (2026-11-09), the company filed a $125 million at-the-market equity program (2026-11-10) and reported third-quarter results (2026-11-10 and 2026-11-11). H.C. Wainwright then raised its price target to $16 (2026-11-11). A virtual Analyst Day on 2026-11-13 and the Jefferies conference on 2026-11-16 restate known data. The shares now price a favourable interim before it exists.\n\nThe company's 2026-09-30 release reported that 9 of 14 patients (64%) in cohorts 5–9 stayed in clinical remission 52 weeks after one dose. The top-dose cohort had 3 patients, and 2 stayed in remission. All published efficacy results are open-label.\n\n## Bull Case\n\n- **The readout has its full sample.** The company announced on 2026-10-15 that the blinded Phase 2b portion reached 120 patients. The interim therefore carries more weight than the 14-patient open-label set.\n- **Durability is the product claim.** Remission across cohorts 5–9 was 53% (10/19) at 12 weeks, 78% (14/18) at 24 weeks, 61% (11/18) at 36 weeks and 64% (9/14) at 52 weeks (company release, 2026-09-30). The comparison is daily oral budesonide (Takeda's Eohilia) and weekly Dupixent injections.\n- **Safety fits local delivery.** The 2026-09-30 release reported no oral candidiasis, no adrenal insufficiency and no glucose abnormalities across all ten cohorts.\n- **Cash covers the readout.** At 2026-09-30 the company held $75.2M in cash and equivalents and $51.2M in short-term investments, and it guides runway into the second half of 2028 (Q3 2026 results, as reported by Panabee). Q3 loss per share was $0.23 against a $0.28 estimate (2026-11-10 headline).\n- **Analyst support is widening.** RBC Capital Markets initiated at Outperform on 2026-11-09. H.C. Wainwright maintained Buy and raised its target to $16 on 2026-11-11. BB Biotech, a Swiss-listed biotech investment company, was reported on 2026-10-23 to have initiated a position.\n\n## Bear Case\n\n- **The efficacy sample is small.** The 52-week figure covers 14 patients and the top-dose cohort has 3. EoE symptom scores also move in placebo arms, and no EP-104GI result includes a control group.\n- **A $125M equity program is now in place.** The company established an at-the-market program of up to $125 million on 2026-11-10 and said it has no current plan to use it in the near term. The 2026-02-20 offering sold 7,607,145 shares at $7.00 plus 1,428,571 pre-funded warrants, and shares outstanding were 65.5M at 2026-06-30.\n- **The run-up leaves less room for a neutral result.** The close rose from $6.60 on 2026-11-05 to $8.06 on 2026-11-11, before an Analyst Day the company itself hosts.\n- **The primary endpoint is undisclosed.** The company's 2026-09-30 and 2026-10-15 releases give December 2026 timing but no endpoint. The 2026-11-13 Analyst Day may name it.\n- **The timing has no day attached.** The company guides \"December 2026\" only. A slip into 2027 would leave the case unresolved.\n\n## Setup & Price Structure\n\nThe shares closed at $8.06 on 2026-11-11, above the 50-day average of $7.62 and the 200-day average of $7.24. The 3-month change is 20.8%. The close is 13.5% below the 52-week intraday high of $9.32 set on 2026-01-21, and the 52-week closing low is $5.81 on 2026-07-24.\n\nRecent closes were $6.76 on 2026-11-04, $6.60 on 2026-11-05, $6.89 on 2026-11-06, $7.42 on 2026-11-09 and $7.63 on 2026-11-10. The shares moved back above the $7.00 February offering price on 2026-11-09 after closing below it on 2026-11-05.\n\nThe call is that November events restate known data and the placebo-controlled interim decides the direction. It is wrong if the company discloses new patient data, an endpoint or a dose-response detail on 2026-11-13 that lifts the shares on its own.\n\n## Catalyst Calendar\n\n- **2026-11-16:** Jefferies Global Healthcare Conference presentation, London. A further management update ahead of the December interim.\n- **~2026-12-15 (est.):** Interim results from the placebo-controlled Phase 2b portion of RESOLVE (company guides December 2026). The first placebo-controlled read on EP-104GI; it shows whether open-label durability survives a control arm.\n\n## Elapsed catalysts\n\n- **2026-11-13:** Virtual Analyst Day on EP-104GI in eosinophilic esophagitis, 8:30am ET. The main chance for the company to describe the interim design and primary endpoint before the readout. *(passed)*\n\n## What Would Change Our Mind\n\nA daily close above $9.10, over the late-September 2026 data-release peak, which would show the shares leading the S&P 500. A December 2026 interim in which EP-104GI arms separate from placebo on the primary endpoint would also show the shares leading.\n\n## Correlation Notes\n\nEPRX trades on its own trial timeline, not on a sector driver. Its readout depends on placebo response in EoE symptom scores, which is company-specific.\n\nRead-across comes from EoE competitors: Takeda's Eohilia and Regeneron and Sanofi's Dupixent set the efficacy bar. Small-cap biotech funding conditions affect any financing that follows the readout, including use of the at-the-market program.",
  "first_seen": "2026-11-10",
  "last_analyzed": "2026-11-12T17:11:17+00:00",
  "last_synthesized": "2026-11-12",
  "date_modified": "2026-11-12",
  "license": "Content © FrontierPicks. Cite the canonical URL."
}